US-Astronaut Terry Virts bereitet bei einem Weltraumspaziergang die ISS auf kommende Raumfahrzeuge vor.
Mittwoch, 06.07.2022 23:16 von | Aufrufe: 172

SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations

US-Astronaut Terry Virts bereitet bei einem Weltraumspaziergang die ISS auf kommende Raumfahrzeuge vor. ©NASA's Marshall Space Flight Center https://creativecommons.org/licenses/by/2.0/

PR Newswire

NEW YORK, July 6, 2022 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

F-star Therapeutics, Inc. (NASDAQ: FSTX) 

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of F-star Therapeutics, Inc. (NASDAQ: FSTX), in connection with the proposed acquisition of FSTX by invoX Pharma via a tender offer. Under the terms of the merger agreement, FSTX shareholders will receive $7.12 in cash for each share of FSTX common stock owned. If you own FSTX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/fstx

Zendesk, Inc. (NYSE: ZEN)


ARIVA.DE Börsen-Geflüster

Kurse

-  
0,00%
Epizyme Chart
F-star Therapeutics Chart
-  
0,00%
Radius Health Chart
-  
0,00%
Zendesk Chart

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Zendesk, Inc. (NYSE: ZEN), in connection with the proposed acquisition of ZEN by investment firms Permira and Hellman & Friedman LLC. Under the terms of the merger agreement, ZEN shareholders will receive $77.50 in cash for each share of ZEN common stock owned. If you own ZEN shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/zen 

Radius Health, Inc. (NASDAQ: RDUS)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Radius Health, Inc. (NASDAQ: RDUS), in connection with the proposed acquisition of RDUS by Gurnet Point Capital and Patient Square Capital via tender offer. Under the terms of the merger agreement, RDUS shareholders will receive $ 10.00 per share plus a Contingent Value Right (CVR) of $1.00 per share payable upon TYMLOS® net sales reaching $300 million during any consecutive 12-month period prior to December 31, 2025. If you own RDUS shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/rdus 

Epizyme, Inc. (NASDAQ: EPZM)

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Epizyme, Inc. (NASDAQ: EPZM), in connection with the proposed acquisition of EPZM by Ipsen S.A. via tender offer. Under the terms of the merger agreement, EPZM shareholders will receive $1.45 in cash, plus one contingent value right (CVR) for each share of EPZM common stock owned. If you own EPZM shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslaw.co/news-and-cases/epzm

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-weiss-law-reminds-fstx-zen-rdus-and-epzm-shareholders-about-its-ongoing-investigations-301581891.html

SOURCE Weiss Law

Werbung

Mehr Nachrichten zur Epizyme Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News